Introduction of an Omega-3 Enriched Oral Supplementation for Cancer Patients Close to the First Chemotherapy: May It Be a Factor for Poor Compliance?

REFERENCES

• Garófolo A and Petrilli AS: Omega-3 and 6 fatty acids balance in inflammatory response in patients with cancer and cachexia. Braz J Nutr 19, 611–621, 2006.
   Google Scholar
• Ries A, Trottenberg P, Elsner F, Stiel S, Haugen D, et al.: A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliat Med 26, 294–304, 2012.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12, 489–495, 2011.
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, et al.: Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics.” Clin Nutr 29, 154–159, 2010.
   PubMed Web of Science ®Google Scholar
• McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Cur Opin Clin Nutr Metab Care 12, 223–226, 2009.
   PubMed Web of Science ®Google Scholar
• Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, et al.: Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 91, 439–446, 2006.
   PubMed Web of Science ®Google Scholar
• Barber MD: The pathophysiology and treatment of cancer cachexia. Nutr Clin Pract 17, 203–209, 2002.
   PubMedGoogle Scholar
• van der Meij BS, Langius JAE, Smit EF, Spreeuwenberg MD, von Blomberg BME, et al.: Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr 140, 1774–1780, 2010.
   PubMed Web of Science ®Google Scholar
• Finocchiaro C, Segre O, Fadda M, Monge T, Scigliano M, et al.: Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr 108, 327–333, 2012.
   PubMed Web of Science ®Google Scholar
• Gomez-Candela C, Sanz MV, Horrisberger A, Kohen VL, Bermejo LM, et al.: Efficacy evaluation of an oral powder supplement enriched with eicosapentaenoic acid in cancer patients. Nutr Hosp 26, 1385–1393, 2011.
   PubMed Web of Science ®Google Scholar
• Murphy RA, Yeung E, Mazurak VC, and Mourtzakis M: Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer 105, 1469–1473, 2011.
   PubMed Web of Science ®Google Scholar
• Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, et al.: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with non-small cell lung cancer receiving chemotherapy. Cancer 117, 1775–1782, 2011.
   PubMed Web of Science ®Google Scholar
• Silva JAP, Trindade EBSM, Fabre MES, Menegotto VM, Gevaerd S, et al.: Fish oil supplement alters markers of inflammatory and nutritional status in colorectal cancer patients. Nutr Cancer 64, 267–273, 2012.
   PubMed Web of Science ®Google Scholar
• van der Meij BS, Langius JAE, Spreeuwenberg MD, Slootmaker SM, Paul MA, et al.: Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT. Eur J Clin Nutr 66, 399–404, 2012.
   PubMed Web of Science ®Google Scholar
• Barber M D, Preston T, McMillan DC, Slater C, Ross JA, et al.: Modulation of the liver export protein synthetic response to feeding by an n-3 fatty-acid-enriched nutritional supplement is associated with anabolism in cachectic cancer patients. Clin Sci 106, 359–364, 2004.
   PubMed Web of Science ®Google Scholar
• Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, et al.: Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer 101, 370–378, 2004.
   PubMed Web of Science ®Google Scholar
• Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, et al.: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52, 1479–1486, 2003.
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, et al.: Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 87, 53–58, 2000.
   PubMed Web of Science ®Google Scholar
• Read JA, Beale PJ, Volker DH, Smith N, Childs A, et al.: Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer 15, 301–307, 2007.
   PubMed Web of Science ®Google Scholar
• Barber MD, Ross JA, Preston T, Shenkin A, Fearon KCH: Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr 129, 1120–1125, 1999.
   PubMed Web of Science ®Google Scholar
• Calder PC: Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 75, 645–662, 2013.
   PubMed Web of Science ®Google Scholar
• Taylor LA, Pletschen L, Arends J, Unger C, and Massing U: Marine phospholipids: a promising new dietary approach to tumor-associated weight loss. Support Care Cancer 18, 159–170, 2010.
   PubMed Web of Science ®Google Scholar
• Trabal J, Leyes P, Forga M, and Maurel J: Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition. Nutr Hosp 25, 736–740, 2010.
   PubMed Web of Science ®Google Scholar
• Detsky AS, Baker JP, Johnston N, Whittaker S, Mendelson RA, et al.: What is subjective global assessment of nutritional status? J Parenter Enteral Nutr 11, 8–13, 1987.
   PubMed Web of Science ®Google Scholar
• Ottery FD: Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition 12, 15–19, 1996.
   PubMed Web of Science ®Google Scholar
• Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, et al.: Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 24, 3401–3407, 2006.
   PubMed Web of Science ®Google Scholar
• Bruera E, Strasser F, Palmer JL, Willey J, Calder K, et al.: Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 21, 129–134, 2003.
   PubMed Web of Science ®Google Scholar
• Coolbrandt A, Van den Heede K, Vanhove E, De Bom A, Milisen K, et al.: Immediate versus delayed self-reporting of symptoms and side effects during chemotherapy: does timing matter? Eur J Oncol Nurs 15, 130–136, 2011.
   PubMed Web of Science ®Google Scholar
• Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, et al.: Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117, 3774–3780, 2011.
   PubMed Web of Science ®Google Scholar
• Colomer R, Moreno-Nogueira JM, García-Luna PP, García-Peris P, Zarazaga A, et al.: n-3 Fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 97, 823–831, 2007.
   PubMed Web of Science ®Google Scholar
• Barber MD, Ross JA, Voss AC, Tisdale MJ, and Fearon KC: The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81, 80–86, 1999.
   PubMed Web of Science ®Google Scholar